Part of the funding will be used to advance Jennerex’ vaccines.
The Ontario Institute for Cancer Research awarded a four-year, C$10 million ($8.9 million) grant to the Centre for Cancer Therapeutics at Ottawa Hospital Research Institute (OHRI). A major portion of this money will fund work in the lab of John Bell, Ph.D., Jennerex’ chief collaborator for oncolytic viral therapeutics.
Jennerex’ products are in Phase I and II testing and have reportedly shown positive safety and efficacy results. They are targeted at various solid tumors. Furtherst along is JX-594 for liver cancer. The Mulcahy Manufacturing Unit at OHRI, Ontario’s first GMP facility dedicated to oncolytic virus production, is undertaking manufacturing for Jennerex.
Jennerex oncolytic virus products are genetically modified vaccine viruses designed to target and destroy only cancer cells while ignoring healthy cells.
